Two patients died, CD28/PD-L1/CTLA-4 triple immunotherapy clinical trial terminated
ADC评论
October 26, 2022
On October 24, Alpine Immune Sciences announced that it had terminated two clinical trials of the conditional CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor davoceticept
